Please assess the completion status of the following clinical trial:

Trial Title: A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Women 18 years of age or older, who are either: Postmenopausal or Pre/perimenopausal women with medically-induced menopause by treatment with agents to induce chemical menopause.~* Histologically or cytologically proven diagnosis of breast cancer with evidence of metastasis.~* Documentation of estrogen receptor positive ((ER+), human epidermal growth factor receptor 2 (HER2 negative (HER2-)) tumor.~* Dose Escalation Portion: Patients must satisfy one of the following criteria:~  * Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression who are candidates for a letrozole-containing regimen, with palbociclib.~ * Fulvestrant combination cohort (F): MBC with progression who are candidates for a fulvestrant containing regimen, with palbociclib.~* Dose Expansion Portion: Patients must satisfy one of the following criteria:~  * Arm A: MBC with progression and no prior endocrine based systemic therapy in the metastatic setting;~ * Arm B: MBC with progression during or following one prior endocrine based systemic therapy in the metastatic setting, with no prior therapy with any cyclin-dependent kinase (CDK) inhibitor;~ * Arm C/Arm D: MBC with progression during or following one or two prior endocrine based systemic therapies in the metastatic setting, and following prior therapy with a CDK inhibitor.~* Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.~* Bone only patients during dose escalation portion.~* Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not available.~* Eastern Cooperative Oncology Group \[ECOG\] performance must be 0 or 1.~* Adequate bone marrow, renal and liver function.~Exclusion Criteria:~* Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase (PI3K) inhibitor.~* More than 1 line of prior chemotherapy in the treatment of metastatic or locally advanced/recurrent disease.~* Bone only patients during expansion/efficacy portion.~* Patients with advanced/metastatic disease who have symptomatic visceral spread, and who have life threatening complications needing immediate therapy, such as massive uncontrolled effusions \[pleural, pericardial, peritoneal\], pulmonary lymphangitis, and over 50% liver replacement with tumor.~* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.~* Active bacterial, fungal or viral infection.~* Uncontrolled or significant cardiovascular disease.~* Radiation therapy within 4 weeks of investigational product.~* Cytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3 4 week schedule or 2 weeks of investigational product if immediate prior regimen consisted of weekly therapy.~* Any other anti cancer agents (eg, hormonal, biological, investigational) within 5 times the half life prior to investigational product.~* Impairment of gastro intestinal (GI) function or GI disease.~* Pregnant female patients; breastfeeding female patients; and female patients of childbearing potential who are unwilling or unable to use 2 highly effective methods of contraception as outlined in this protocol for the duration of the study and for 90 days.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Letrozole Cohort (Type: EXPERIMENTAL): Letrozole combination cohort in dose escalation
- Fulvestrant cohort (Type: EXPERIMENTAL): Fulvestrant combination cohort in dose escalation
- ARM A (Type: EXPERIMENTAL): Gedatolisib + palbociclib + letrozole in dose expansion
- ARM B (Type: EXPERIMENTAL): Gedatolisib + palbociclib + fulvestrant in dose expansion
- ARM C (Type: EXPERIMENTAL): Gedatolisib + palbociclib + fulvestrant in dose expansion
- Arm D (Type: EXPERIMENTAL): Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete